Approval · Notice of Compliance 14287 · 2013
TEVA-ELETRIPTAN: Notice of Compliance 14287
Issued April 12, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14287
- Date
- April 12, 2013
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- 5ht1 receptor agonist; migraine therapy
- Canadian reference product
- RELPAX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-ELETRIPTAN | 02382091 | Marketed |
| TEVA-ELETRIPTAN | 02382105 | Marketed |
Medicinal ingredients
- ELETRIPTAN HYDROBROMIDE 20 MG per TAB
- ELETRIPTAN HYDROBROMIDE 40 MG per TAB